Pediatric

« Previous 12 Next »
Viewing Page 1 of 2 | Showing Results 1 - 10 of 15

A Phase 3 Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy)

This phase III trial studies how well blinatumomab works in combination with chemotherapy in treating patients with or without Down syndrome and...

Brenda Wittman, M.D.
  • Alaska Research
  • Providence Alaska Medical Center

Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)

This partially randomized phase II/III trial studies how well cisplatin and combination chemotherapy works in treating children and young adults...

Brenda Wittman, M.D.
  • Alaska Pediatric Oncology
  • Alaska Research
  • Providence Alaska Medical Center

A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients

This phase II trial studies how well reduced doses of radiation therapy to the brain and spine (craniospinal) and chemotherapy work in treating...

Brenda Wittman, M.D.
  • Alaska Research
  • Providence Alaska Medical Center

A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (NSC# 102816) to Chemotherapy in Infants With Acute Lymphoblastic Leukemia (ALL) and KMT2A (MLL) Gene Rearrangement

This pilot phase II trial studies the side effects of azacitidine and combination chemotherapy in infants with acute lymphoblastic leukemia and...

Brenda Wittman, M.D.
  • Alaska Pediatric Oncology
  • Alaska Research
  • Providence Alaska Medical Center

A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864, IND# 122782) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS)

This randomized phase III trial studies how well combination chemotherapy (vincristine sulfate, dactinomycin, cyclophosphamide alternated with...

Brenda Wittman, M.D.
  • Alaska Pediatric Oncology
  • Alaska Research
  • Providence Alaska Medical Center

ONC AGCT1532 - A Randomized Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-Risk Germ Cell Tumors

The purpose of this study is to determine whether accelerated BEP chemotherapy is more effective than standard BEP chemotherapy in males with...

Brenda Wittman, M.D.
  • Alaska Research
  • Providence Alaska Medical Center

Project:EveryChild A Registry, Eligibility Screening, Biology and Outcome Study

This research trial studies the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients...

Brenda Wittman, M.D.
  • Alaska Research
  • Providence Alaska Medical Center

Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-high-risk Neuroblastoma

This phase III trial studies how well response and biology-based risk factor-guided therapy works in treating younger patients with non-high risk...

Brenda Wittman, M.D.
  • Alaska Research
  • Providence Alaska Medical Center

ONC AGCT1531-A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors

This partially randomized phase III trial studies how well active surveillance, bleomycin, carboplatin, etoposide, or cisplatin work in treating...

Brenda Wittman, M.D.
  • Alaska Research
  • Providence Alaska Medical Center

Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome

This phase III trial studies response-based chemotherapy in treating newly diagnosed acute myeloid leukemia or myelodysplastic syndrome in younger...

Brenda Wittman, M.D.
  • Alaska Research
  • Providence Alaska Medical Center
« Previous 12 Next »
Viewing Page 1 of 2 | Showing Results 1 - 10 of 15